Eight new meds backed for approval at April EMA/CHMP meeting

1 May 2020

Recommendations were given for marketing authorizations of four novel drugs and four biosimilars or hybrid medicines following the April 28-30 meeting of the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). The recommendations will be now be reviewed by the European Commission, with a decision likely in the next two/three months.

The Committee recommended granting a marketing authorization for Swiss pharma giant Novartis’ (NOVN: VX) Enerzair Breezhaler, the first triple combination therapy for the treatment of asthma which includes an optional smart electronic sensor. Enerzair Breezhaler consists of a fixed dose combination of three active substances (indacaterol/glycopyrronium/mometasone) in capsules, to be administered using an inhaler.

The CHMP also adopted a positive opinion for Novartis’ Zimbus Breezhaler (indacaterol/glycopyrronium/mometasone) which is a duplicate of Enerzair Breezhaler for the treatment of asthma.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK